Greatmark Investment Partners Inc. Decreases Stock Holdings in Amgen Inc. $AMGN

Greatmark Investment Partners Inc. trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 70,751 shares of the medical research company’s stock after selling 1,552 shares during the period. Amgen makes up 2.7% of Greatmark Investment Partners Inc.’s investment portfolio, making the stock its 11th largest holding. Greatmark Investment Partners Inc.’s holdings in Amgen were worth $23,158,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. raised its holdings in shares of Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the last quarter. Curtis Advisory Group LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $1,669,000. Davis Capital Management purchased a new position in shares of Amgen during the third quarter valued at approximately $1,841,000. Finally, D.A. Davidson & CO. raised its holdings in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent research reports. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 target price on shares of Amgen in a research report on Wednesday, April 8th. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Mizuho boosted their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. TD Cowen restated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average price target of $356.24.

Amgen Stock Performance

AMGN opened at $355.30 on Friday. The firm has a market cap of $191.75 billion, a P/E ratio of 24.97, a PEG ratio of 3.65 and a beta of 0.47. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a 50 day simple moving average of $362.91 and a two-hundred day simple moving average of $337.70. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.